K
5.67
-0.18 (-3.08%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Kyverna Therapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | 0.0 |
| 宏观环境 | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | 0.04 |
|
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 12.04% |
| 机构持股比例 | 68.57% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Gordonmd Global Investments Lp | 30 Jun 2026 | 4,244,818 |
| Gilead Sciences, Inc. | 30 Jun 2026 | 4,126,119 |
| Aigh Capital Management Llc | 30 Jun 2026 | 2,795,797 |
| Insight Holdings Group, Llc | 30 Jun 2026 | 989,054 |
| Propel Bio Management, Llc | 30 Jun 2026 | 883,198 |
| Woodline Partners Lp | 30 Jun 2026 | 845,325 |
该时间范围内无数据。
该时间范围内无数据。
投资组合